In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events

BACKGROUND AND OBJECTIVES: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt...

Descripción completa

Detalles Bibliográficos
Autores principales: Dans, Antonio L., Teo, Koon, Gao, Peggy, Chen, Jyh-Hong, Jae-Hyung, Kim, Yusoff, Khalid, Chaithiraphan, Suphachai, Zhu, Jun, Lisheng, Liu, Yusuf, Salim
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006195/
https://www.ncbi.nlm.nih.gov/pubmed/21200437
http://dx.doi.org/10.1371/journal.pone.0013694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006195/
https://www.ncbi.nlm.nih.gov/pubmed/21200437
http://dx.doi.org/10.1371/journal.pone.0013694

Ejemplares similares